181 related articles for article (PubMed ID: 32172474)
21. Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma.
Shi J; Yang XR; Ballew B; Rotunno M; Calista D; Fargnoli MC; Ghiorzo P; Bressac-de Paillerets B; Nagore E; Avril MF; Caporaso NE; McMaster ML; Cullen M; Wang Z; Zhang X; ; ; ; Bruno W; Pastorino L; Queirolo P; Banuls-Roca J; Garcia-Casado Z; Vaysse A; Mohamdi H; Riazalhosseini Y; Foglio M; Jouenne F; Hua X; Hyland PL; Yin J; Vallabhaneni H; Chai W; Minghetti P; Pellegrini C; Ravichandran S; Eggermont A; Lathrop M; Peris K; Scarra GB; Landi G; Savage SA; Sampson JN; He J; Yeager M; Goldin LR; Demenais F; Chanock SJ; Tucker MA; Goldstein AM; Liu Y; Landi MT
Nat Genet; 2014 May; 46(5):482-6. PubMed ID: 24686846
[TBL] [Abstract][Full Text] [Related]
22. Identification of
Marques IJ; Gomes I; Pojo M; Pires C; Moura MM; Cabrera R; Santos C; van IJcken WFJ; Teixeira MR; Ramalho JS; Leite V; Cavaco BM
Thyroid; 2021 Sep; 31(9):1366-1375. PubMed ID: 33906393
[No Abstract] [Full Text] [Related]
23. Familial non-medullary thyroid cancer: unraveling the genetic maze.
Peiling Yang S; Ngeow J
Endocr Relat Cancer; 2016 Dec; 23(12):R577-R595. PubMed ID: 27807061
[TBL] [Abstract][Full Text] [Related]
24. The wide spectrum of POT1 gene variants correlates with multiple cancer types.
Calvete O; Garcia-Pavia P; Domínguez F; Bougeard G; Kunze K; Braeuninger A; Teule A; Lasa A; Ramón Y Cajal T; Llort G; Fernández V; Lázaro C; Urioste M; Benitez J
Eur J Hum Genet; 2017 Nov; 25(11):1278-1281. PubMed ID: 28853721
[TBL] [Abstract][Full Text] [Related]
25. Lack of mutations of the telomerase RNA component in familial papillary thyroid cancer with short telomeres.
Cantara S; Capuano S; Capezzone M; Benigni M; Pisu M; Marchisotta S; Pacini F
Thyroid; 2012 Apr; 22(4):363-8. PubMed ID: 22304389
[TBL] [Abstract][Full Text] [Related]
26. Novel Susceptibility Genes Drive Familial Non-Medullary Thyroid Cancer in a Large Consanguineous Kindred.
Majdalani P; Yoel U; Nasasra T; Fraenkel M; Haim A; Loewenthal N; Zarivach R; Hershkovitz E; Parvari R
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175943
[TBL] [Abstract][Full Text] [Related]
27. BROX haploinsufficiency in familial nonmedullary thyroid cancer.
Pasquali D; Torella A; Accardo G; Esposito D; Del Vecchio Blanco F; Salvatore D; Sabatino P; Pacini F; Barbato F; Castagna MG; Cantara S; Nigro V
J Endocrinol Invest; 2021 Jan; 44(1):165-171. PubMed ID: 32385852
[TBL] [Abstract][Full Text] [Related]
28. A
Abu Shtaya A; Kedar I; Bazak L; Basel-Salmon L; Barhom SF; Naftali M; Eskin-Schwartz M; Birk OS; Polager-Modan S; Keidar N; Reznick Levi G; Levi Z; Yablonski-Peretz T; Mahamid A; Segol O; Matar R; Bareli Y; Azoulay N; Goldberg Y
Genes (Basel); 2024 Mar; 15(3):. PubMed ID: 38540414
[TBL] [Abstract][Full Text] [Related]
29. Identification of a Novel Germline
Hu Y; Han Z; Guo H; Zhang N; Shen N; Jiang Y; Huang T
Biomedicines; 2024 Jan; 12(1):. PubMed ID: 38275415
[TBL] [Abstract][Full Text] [Related]
30. Identification of somatic TERT promoter mutations in familial nonmedullary thyroid carcinomas.
Marques IJ; Moura MM; Cabrera R; Pinto AE; Simões-Pereira J; Santos C; Menezes FD; Montezuma D; Henrique R; Rodrigues Teixeira M; Leite V; Cavaco BM
Clin Endocrinol (Oxf); 2017 Oct; 87(4):394-399. PubMed ID: 28502101
[TBL] [Abstract][Full Text] [Related]
31. POT1 loss-of-function variants predispose to familial melanoma.
Robles-Espinoza CD; Harland M; Ramsay AJ; Aoude LG; Quesada V; Ding Z; Pooley KA; Pritchard AL; Tiffen JC; Petljak M; Palmer JM; Symmons J; Johansson P; Stark MS; Gartside MG; Snowden H; Montgomery GW; Martin NG; Liu JZ; Choi J; Makowski M; Brown KM; Dunning AM; Keane TM; López-Otín C; Gruis NA; Hayward NK; Bishop DT; Newton-Bishop JA; Adams DJ
Nat Genet; 2014 May; 46(5):478-481. PubMed ID: 24686849
[TBL] [Abstract][Full Text] [Related]
32. Current Knowledge of Germline Genetic Risk Factors for the Development of Non-Medullary Thyroid Cancer.
Hińcza K; Kowalik A; Kowalska A
Genes (Basel); 2019 Jun; 10(7):. PubMed ID: 31247975
[TBL] [Abstract][Full Text] [Related]
33. Identification of NID1 as a novel candidate susceptibility gene for familial non-medullary thyroid carcinoma using whole-exome sequencing.
de Mello LEB; Carneiro TNR; Araujo AN; Alves CX; Galante PAF; Buzatto VC; das Graças de Almeida M; Vermeulen-Serpa KM; de Lima Vale SH; José de Pinto Paiva F; Brandão-Neto J; Cerutti JM
Endocr Connect; 2022 Jan; 11(1):. PubMed ID: 34941562
[TBL] [Abstract][Full Text] [Related]
34. [A Familial Non Medullary Thyroid Carcinoma (FNMTC) : a clinical and genetic update].
Valdes-Socin H; Palmeira L; Burlacu MC; Daly AF; Bours V; Beckers A
Rev Med Liege; 2016 Dec; 71(12):557-561. PubMed ID: 28387096
[TBL] [Abstract][Full Text] [Related]
35. Identification of
Jiang YJ; Xia Y; Hu YX; Han ZJ; Guo AY; Huang T
Thyroid; 2024 May; 34(5):583-597. PubMed ID: 38411500
[No Abstract] [Full Text] [Related]
36. Germline POT1 Deregulation Can Predispose to Myeloid Malignancies in Childhood.
Michler P; Schedel A; Witschas M; Friedrich UA; Wagener R; Mehtonen J; Brozou T; Menzel M; Walter C; Nabi D; Pearce G; Erlacher M; Göhring G; Dugas M; Heinäniemi M; Borkhardt A; Stölzel F; Hauer J; Auer F
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769003
[TBL] [Abstract][Full Text] [Related]
37. Familial non-medullary thyroid cancer: a critical review.
Capezzone M; Robenshtok E; Cantara S; Castagna MG
J Endocrinol Invest; 2021 May; 44(5):943-950. PubMed ID: 33025555
[TBL] [Abstract][Full Text] [Related]
38. Germline
Andreotti V; Vanni I; Pastorino L; Ghiorzo P; Bruno W
Genes (Basel); 2024 Jan; 15(1):. PubMed ID: 38254993
[TBL] [Abstract][Full Text] [Related]
39. CHEK2 germline variants identified in familial nonmedullary thyroid cancer lead to impaired protein structure and function.
Pires C; Marques IJ; Valério M; Saramago A; Santo PE; Santos S; Silva M; Moura MM; Matos J; Pereira T; Cabrera R; Lousa D; Leite V; Bandeiras TM; Vicente JB; Cavaco BM
J Biol Chem; 2024 Mar; 300(3):105767. PubMed ID: 38367672
[TBL] [Abstract][Full Text] [Related]
40. Familial non-medullary thyroid carcinoma (FNMTC): analysis of fPTC/PRN, NMTC1, MNG1 and TCO susceptibility loci and identification of somatic BRAF and RAS mutations.
Cavaco BM; Batista PF; Martins C; Banito A; do Rosário F; Limbert E; Sobrinho LG; Leite V
Endocr Relat Cancer; 2008 Mar; 15(1):207-15. PubMed ID: 18310288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
